Theravance Biopharma, Inc.
DelistedCIK 1583107fmd_0MR32M6JM5P545CNWXKG60X71DManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Jun 30, 2026, 55 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 49 | 15 | 60 | 73 | 72 | 55 | 51 | 57 | 64 | 107 |
| Cost of revenue | 3 | 6 | – | – | – | – | – | – | – | – |
| Gross profit | 46 | 9 | – | – | – | – | – | – | – | – |
| Research and development | 142 | 174 | 201 | 219 | 261 | 194 | 63 | 41 | 38 | 37 |
| Selling, general and administrative | 85 | 96 | 97 | 106 | 109 | 99 | 67 | 70 | 69 | 74 |
| Total operating expenses | 229 | 276 | 299 | 325 | 369 | 313 | 143 | 113 | 111 | 111 |
| Operating income | (180) | (260) | (239) | (252) | (298) | (258) | (92) | (56) | (47) | (4) |
| Interest expense | 1 | 9 | 10 | 32 | 9 | 9 | 6 | 2 | 3 | 2 |
| Other non-operating income (expense) | 1 | 5 | 12 | 8 | 3 | 1 | 9 | 9 | 5 | 10 |
| Income before taxes | (181) | (272) | (226) | (242) | (303) | (265) | (93) | (49) | (45) | 129 |
| Income tax expense | 10 | 14 | (11) | (5) | (9) | (0) | 0 | 6 | 12 | 23 |
| Net income from continuing operations | (191) | (285) | (216) | (236) | (295) | (265) | (93) | (55) | (56) | 106 |
| Net income | (191) | (285) | (216) | (236) | (278) | (199) | 872 | (55) | (56) | 106 |
| Net income to common shareholders | – | – | – | – | – | – | – | – | (56) | 106 |